Descriptions:
Prof G Markets examines Google’s fourth-quarter 2025 earnings in detail, joined by Scott Devitt, managing director of equity research at Wedbush Securities, who breaks down the numbers and their implications for the broader AI investment cycle.
Google reported annual revenue exceeding $400 billion for the first time, driven by 17% search growth — accelerating despite AI Overview integrations — and 48% year-over-year cloud revenue growth, which significantly beat the 38% analyst consensus. The headline that rattled markets was 2026 capital expenditure guidance of $175 to $185 billion, nearly double 2025’s capex spend and roughly $55 billion above Wall Street’s forecast. The stock dropped 7% after hours before recovering as investors reassessed the long-term growth implications against the near-term spend.
Devitt contextualizes the reaction as part of a broader market digestion phase: investors are simultaneously processing massive AI infrastructure spend from Alphabet, Meta, and other hyperscalers while struggling to assign forward revenue multiples to investments that haven’t yet translated into operating profit. He argues the capex is strategically correct but acknowledges the market is in an uncomfortable period where growth signals and spending signals are pulling valuations in opposite directions.
The episode also covers the GLP-1 drug market, including Novo Nordisk’s early oral semaglutide rollout — approximately 200,000 patients in the first four weeks at $150 per month — and the competitive dynamics ahead of Eli Lilly’s pending FDA approval for its own oral GLP-1 candidate, Orforglipron.
📺 Source: The Prof G Pod – Scott Galloway · Published February 05, 2026
🏷️ Format: News Analysis
